Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
Oak Ridge Institute for Science and Education invites applicants for a fellowship with FDA-CDER in Silver Spring, MD. The opportunity focuses on statistical evaluation of TD50 and BMD approaches to derive acceptable intakes for carcinogenic impurities, through simulation studies.
Mentored by Meiyu Shen, fellows gain experience communicating statistical findings in a regulatory-science setting. Start date is October 2026, for an initial one-year appointment with potential renewal.
U.S. Food and Drug Administration (FDA)
FDA-CDER-2026-0146
8/31/2027 3:00:00 PM Eastern Time Zone
Applications will be reviewed on a rolling-basis.
A research opportunity is available in the Office of Immunology and Inflammation (OII), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.
You will have the opportunity to participate in a statistical evaluation of tumorigenic dose 50 (TD50) and benchmark dose (BMD) approaches for deriving acceptable intakes of carcinogenic impurities by simulation studies. The goal of this project is to provide a stronger statistical basis for interpreting TD50- and BMD-based acceptable intakes in regulatory risk assessment.
The mentor for this opportunity is Meiyu Shen (meiyu.shen@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.
October 2026. Start date is flexible and will depend on a variety of factors.
The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.
The appointment is full-time.
The participant will receive a monthly stipend commensurate with educational level and experience.
This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should be currently pursuing or have received a master's degree in the one of the relevant fields.
I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.) and I have read the FDA Ethics Requirements.